Redhill Biopharm Stock Price, News & Analysis

RedHill Biopharma (Nasdaq: RDHL) reported Q1 2022 net revenues of $18.2 million, down from $22.1 million in Q4 2021, attributed to cyclical Movantik sales trends. The company has implemented a cost reduction plan, expecting $50 million in savings over 18 months, which contributed to a 70% decrease in cash used in operations to $4 million. Talicia® and Movantik® showed strong growth, with prescription increases of 12.8% and 8.6% respectively. The company maintains a cash balance of $45 million and is in discussions for potential acquisitions and external funding for ongoing R&D initiatives.

RedHill Biopharma Ltd. (Nasdaq: RDHL) will report its first quarter 2022 financial results on June 23, 2022, at 8:30 a.m. EDT. The company has invited investors to join a conference call, which will include key operational highlights. Interested participants can register and access the event through the company's website. RedHill focuses on gastrointestinal and infectious diseases, promoting drugs like Movantik and Talicia, and is engaged in several late-stage clinical programs.

RedHill Biopharma presented new data analyses on Talicia during Digestive Diseases Week (DDW) 2022, focusing on its efficacy in treating H. pylori infection in patients with diabetes. Findings showed Talicia maintained eradication rates of 91.7% in diabetic patients versus 84.1% in non-diabetic patients. No significant antibiotic resistance was observed. A pharmacokinetic study indicated Talicia's low-dose rifabutin formulation achieves higher intragastric antibiotic exposure, crucial for effective treatment. Talicia addresses a significant unmet need as around 35% of U.S. adults are affected by H. pylori.

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced a definitive agreement for a registered direct offering of 10,563,380 American Depositary Shares (ADSs) at $1.42 per ADS, with expected gross proceeds of approximately $15 million. The offering includes unregistered private warrants for up to 13,204,225 ADSs with an exercise price of $1.48. The net proceeds will be used for working capital, acquisitions, and general corporate purposes. The closing is anticipated on or about May 11, 2022. Cantor Fitzgerald & Co. is the exclusive placement agent for this offering.

RedHill Biopharma (Nasdaq: RDHL) announced that its oral drug candidate, opaganib, demonstrated potent in vitro activity against the Omicron variant of SARS-CoV-2, as confirmed by research from the University of Hong Kong. Opaganib's mechanism aims to address viral mutations, maintaining efficacy against Omicron sub-variants. Phase 2/3 clinical data revealed improved viral RNA clearance, reduced mortality by 70%, and faster recovery times in hospitalized patients. Regulatory discussions for potential approval are ongoing across several regions.

RedHill Biopharma (NASDAQ:RDHL) announced promising results for opaganib, a treatment for COVID-19, showing potent in vitro activity against the Omicron variant. Research by The University of Hong Kong indicates that opaganib acts through a unique mechanism that could remain effective against various viral mutations, including sub-variants BA.2 and XE. Phase 2/3 trials revealed a 70% reduction in mortality and a 34% faster recovery time in treated patients. Regulatory discussions for approval are underway across multiple regions, supporting opaganib's potential as a treatment option.

RedHill Biopharma (NASDAQ: RDHL) reported record revenues of $85.8 million for 2021, a 33.2% increase from 2020, driven by the strong performances of Talicia® and Movantik®. The Q4 net revenues were $22.1 million, slightly up from Q3. However, a $9 million impairment related to Aemcolo® resulted in a gross profit decline to $2.7 million. Operating loss for Q4 increased to $20.7 million. The company is focused on cost-containment and expects profitability from commercial operations in 2022. Positive late-stage data for COVID-19 drugs opaganib and RHB-107 were highlighted.

RedHill Biopharma (Nasdaq: RDHL) announced an exclusive licensing agreement with Kukbo Co. Ltd. for its oral drug opaganib, aimed at treating COVID-19 in South Korea. The agreement includes a $1.5 million upfront payment and potential milestone payments of up to $5.6 million, alongside royalties on net sales. Given the recent surge of COVID-19 cases in South Korea, with nearly 4 million cases reported in March, the partnership aims to expedite the drug's availability. Opaganib has shown promise in clinical trials for COVID-19, including improved viral clearance and reduced mortality.

RedHill Biopharma Ltd. (Nasdaq: RDHL) will announce its fourth quarter and full year 2021 financial results on March 17, 2022. A conference call is scheduled for 8:30 a.m. EDT, providing insights into key operational highlights. RedHill focuses on gastrointestinal and infectious diseases, with products like Movantik, Talicia, and Aemcolo. Ongoing late-stage clinical trials include RHB-204 for pulmonary diseases and opaganib for COVID-19 and cancer. More information will be available on their website.